Aqr Capital Management LLC Mersana Therapeutics, Inc. Transaction History

Aqr Capital Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.11 - $2.34 $123,890 - $261,174	-111,613 Reduced 77.96%	31,559 $73,000
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $75,396 - $278,114	71,129 Added 98.73%	143,172 $181,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $117,474 - $364,246	38,141 Added 112.5%	72,043 $237,000
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $405,196 - $711,118	-101,299 Reduced 74.92%	33,902 $139,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $253,052 - $352,033	44,788 Added 49.54%	135,201 $792,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $310,270 - $536,104	67,013 Added 286.38%	90,413 $611,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $5.0 $30,353 - $53,440	10,688 Added 84.08%	23,400 $108,000
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $47,542 - $84,280	12,712 New	12,712 $51,000
Q4 2021 Feb 14, 2022	SELL	$5.48 - $9.86 $67,568 - $121,573	-12,330 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.28 - $18.07 $452,648 - $615,915	-34,085 Reduced 73.44%	12,330 $167,000
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $89,793 - $155,539	5,865 Added 14.46%	46,415 $751,000
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $102,707 - $168,271	-6,099 Reduced 13.07%	40,550 $1.08 Million
Q3 2020 Nov 16, 2020	SELL	$16.2 - $25.7 $98,982 - $157,027	-6,110 Reduced 11.58%	46,649 $869,000
Q2 2020 Aug 17, 2020	BUY	$5.24 - $23.4 $170,572 - $761,716	32,552 Added 161.09%	52,759 $1.24 Million
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $89,112 - $187,520	20,207 New	20,207 $118,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.